Prognostic significance of diffuse increased fluorine-18-fluorodeoxyglucose (F-FDG) uptake within the reticuloendothelial system in lymphoma patients.

Background: As constituents of the reticuloendothelial system, the spleen and bone marrow (BM) have been recognized as integral components of the systemic inflammatory response in cancer contexts, thereby serving as predictive indicators for assessing cancer prognosis. Fluorine-18-fluorodeoxyglucose (F-FDG) positron emission tomography (PET)/computed tomography (CT) has attained widespread utilization for staging, assessing treatment response, and prognostication in lymphoma patients. Several investigations have proposed that focal increased F-FDG uptake in the BM or spleen may correlate with malignant involvement in lymphoma.

Clinical significance of F-FDG-PET/CT for detection of incidental pre-malignant and malignant colonic lesions: correlation with colonoscopic and histopathological results.

Background: Incidental colorectal fluorodeoxyglucose (FDG) uptake, observed during positron emission tomography/computed tomography (PET/CT) scans, attracts particular attention due to its potential to represent both benign and pre-malignant/malignant lesions. Early detection and excision of these lesions are crucial for preventing cancer development and reducing mortality. This research aims to evaluate the correlation between incidental colorectal FDG uptake on PET/CT with colonoscopic and histopathological results.

Development of a radiomic-clinical nomogram for prediction of survival in patients with diffuse large B-cell lymphoma treated with chimeric antigen receptor T cells.

Background: In our current work, an F-FDG PET/CT radiomics-based model was developed to assess the progression-free survival (PFS) and overall survival (OS) of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who received chimeric antigen receptor (CAR)-T cell therapy.

Methods: A total of 61 DLBCL cases receiving F-FDG PET/CT before CAR-T cell infusion were included in the current analysis, and these patients were randomly assigned to a training cohort (n = 42) and a validation cohort (n = 19). Radiomic features from PET and CT images were obtained using LIFEx software, and radiomics signatures (R-signatures) were then constructed by choosing the optimal parameters according to their PFS and OS.

Radioactive Iodine Ablation Can Reduce the Structural Recurrence Rate of Intermediate-Risk Papillary Thyroid Microcarcinoma: A Meta-Analysis.

Background: The incidence of papillary thyroid microcarcinoma (PTMC) has significantly increased in recent years, and the decision to use radioactive iodine (RAI) ablation in low-risk (LR) and intermediate-risk (IR) patients is controversial. The aim of this study was to evaluate whether RAI ablation can reduce the recurrence rate in LR-IR PTMC patients.

Methods: A comprehensive literature search of the PubMed, Embase, Cochrane Library, and Web of Science was conducted according to the PRISMA statement.

Imaging Characteristics and Prognostic Value of Isolated Pulmonary Metastasis from Colorectal Cancer Demonstrated withF-FDG PET/CT.

Objective: Solitary pulmonary lesions (SPNs) in patients with a history of colorectal cancer (CRC) may be attributed to metastatic lung tumors, primary lung cancer, or benign nodules. We aimed to analyze the imaging characteristics of SPNs in CRC patients to differentiate these pulmonary nodules and evaluate the prognostic value of isolated pulmonary metastasis from CRC using F-FDG PET/CT.

Methods: From January 2013 to January 2021, 62 CRC patients with SPNs demonstrated with F-FDG PET/CT were retrospectively enrolled in the present study.

Prognostic Value of Radiomic Features of F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells.

Objective: In the present study, we aimed to evaluate the prognostic value of PET/CT-derived radiomic features for patients with B-cell lymphoma (BCL), who were treated with CD19/CD22 dual-targeted chimeric antigen receptor (CAR) T cells. Moreover, we explored the relationship between baseline radiomic features and the occurrence probability of cytokine release syndrome (CRS).

Methods: A total of 24 BCL patients who received F-FDG PET/CT before CAR T-cell infusion were enrolled in the present study.

Radiomic Features of F-FDG PET in Hodgkin Lymphoma Are Predictive of Outcomes.

Purpose: In the present study, we aimed to investigate whether the radiomic features of baseline F-FDG PET can predict the prognosis of Hodgkin lymphoma (HL).

Methods: A total 65 HL patients (training cohort:  = 49; validation cohort:  = 16) were retrospectively enrolled in the present study. A total of 47 radiomic features were extracted from pretreatment PET images.

Prognostic Value of 2-Deoxy-2-[F]fluoro-D-glucose Positron Emission Tomography/Computed Tomography after Autologous Hematopoietic Stem Cell Transplantation in Lymphoma Using Deauville Scores.

Purpose: In the present study, we mainly aimed to evaluate the prognostic value of 2-deoxy-2-[F]fluoro-D-glucose ([F]F-FDG) positron emission tomography (PET)/computed tomography (CT) after autologous stem cell transplantation (ASCT) in lymphoma. . A total of 76 lymphoma patients who benefited from [F]F-FDG PET-CT (within 3 months and 3-6 months) after ASCT in our institution between April 2010 and December 2019 were enrolled in this retrospective study.

The value of F-FDG PET/CT in the prediction of clinical outcomes of patients with acute leukemia treated with allogeneic hematopoietic stem cell transplantation.

The present study aimed to determine whether F-FDG PET/CT performed before and/or after allogeneic hematopoietic stem cell transplantation (allo-HSCT) can predict clinical outcomes in acute leukemia (AL). A total of 79 examinations comprising 72 patients with AL who underwent F-FDG PET/CT before and/or after allo-HSCT were retrospectively enrolled between January 2011 and January 2019. Outcomes were assessed using overall survival (OS) and disease-free survival (DFS).

Applications of PET in Diagnosis and Prognosis of Leukemia.

As a malignant hematopoietic stem cell disease, leukemia remains life-threatening due to its increasing incidence rate and mortality rate. Therefore, its early diagnosis and treatment play a very important role. In the present work, we systematically reviewed the current applications and future directions of positron emission tomography (PET) in patients with leukemia, especially F-FDG PET/CT.

Prognostic Values of Baseline F-FDG PET/CT in Patients with Peripheral T-Cell Lymphoma.

Purpose: In the present study, we aimed to investigate whether the metabolic parameters on baseline F-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) could be used to predict prognosis in peripheral T-cell lymphomas (PTCL).

Methods: A total of 51 nodal PTCL patients who underwent baseline F-FDG PET/CT were retrospectively evaluated in the present study. Total metabolic tumor volume (TMTV), total lesion glycolysis (TLG), and maximum standardized uptake value (SUV) were also assessed.

Prognostic value of baseline F-FDG PET/CT metabolic parameters in paediatric lymphoma.

Introduction: In the present study, we aimed to investigate the prognostic value of metabolic parameters, including maximum standardized uptake value (SUV ), total metabolic tumour volume (tMTV) and total lesion glycolysis (TLG), measured at baseline F-FDG PET/CT in paediatric lymphoma.

Methods: From March 2013 to April 2019, 47 patients with paediatric lymphoma, including 38 males and nine females with an average age of 14.87 years, who underwent F-FDG PET/CT scan prior to treatment were retrospectively included in this study.

Prognostic values of baseline, interim and end-of therapy F-FDG PET/CT in patients with follicular lymphoma.

Purpose: In the present study, we aimed to investigate the role of baseline, interim and end-of treatment positron emission tomography/computed tomography (PET/CT) in assessing the prognosis of follicular lymphoma (FL).

Methods: A total of 84 FL patients were retrospectively analyzed in this study. Baseline (n=59), interim (n=24, after 2-4 cycles) and end-of treatment (n=43) PET/CT images were re-evaluated, and baseline maximum standardized uptake value (SUV), total metabolic tumor volume (tMTV) and total lesion glycolysis (TLG) were recorded.

Cu-based Radiopharmaceuticals in Molecular Imaging.

Copper-64 (T = 12.7 hours; β: 19%, β: 38%) has a unique decay profile and can be used for positron emission tomography imaging and radionuclide therapy. The well-established coordination chemistry of copper allows for its reaction with different types of chelator systems.

The Role of F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie-Salmon Plus and Other Staging Systems.

We aimed at comparing the Durie-Salmon Plus (DS Plus) staging system based on Italian Myeloma criteria for PET USe (IMPeTUs) with other two staging systems in predicting prognosis of patients with all stages of newly diagnosed multiple myeloma (MM). A total of 33 MM patients were enrolled in this retrospective study. The variation between the DS Plus classification and Durie-Salmon staging system (DSS) or Revised International Staging System (RISS) classification was assessed.